Update on cross-resistance of fluoroquinolones

International Journal of Clinical Practice, Supplement

Volumn , Issue 115, 2000, Pages 94-98

  Garau, J ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL MEMBRANE; CONFERENCE PAPER; DRUG ACTIVITY; DRUG SENSITIVITY; ENZYME ACTIVITY; HAEMOPHILUS INFLUENZAE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS INFECTION;

ANTI-INFECTIVE AGENTS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; QUINOLONES;

EID: 33749212235     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. The in vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone
2. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis
3. Activity of quinolones against mycobacteria
4. The epidemiology of penicillin resistance in Streptococcus pneumoniae
5. Decreased susceptibility d Streptococcus pneumoniae to fluoroquinolones in Canada
6. Basing empiric treatment choices for respiratory tract infection on the results of the Alexander Project
7. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification and differential inhibition by fluoroguinolones
8. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones
9. Ouinolone mode of action
10. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase. IV by quinolones
11. Engineering the specificity of antibacterial fluoroquinolones: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase
12. Antipneumococcal activities of gemifloxacin compared to those of nine other agents
13. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin and other antimicrobial agents against bloodstream isolates of Gram-positive cocci
14. Activities of trovafloxacin, gatifloxacin,clinafloxacin, sparfloxacin, levofloxacin and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model
15. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
16. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
17. Activity of ' gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms
18. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae
19. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group Streptococci
20. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: Evidence for diminished moxifloxacin, sparfloxacin and trovafloxacin efflux